Zhou et al. analyzed the expression of several immune markers (CD8, CD4, Foxp3, and PD-L1) using immunohistochemistry (IHC) in 11 tissue biopsies from patients with CCA receiving anlotinib and toripalimab. Here, CD8A is linked to cholangiocarcinoma.